Safety and Efficacy of Pembrolizumab Prior to Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia

Review Pharmacology & Pharmacy

Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics

Julianne D. Twomey et al.

Summary: ICIs, targeting PD-1 or PD-L1, have become a new standard-of-care for many cancer indications, approved by the FDA. This review focuses on their clinical indications, companion diagnostics, and strategies for identifying predictive biomarkers for guiding their clinical use.

AAPS JOURNAL (2021)

Add to Collection

Article Oncology

Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma

Reid W. Merryman et al.

Summary: Anti-PD-1 monoclonal antibodies have shown high response rates in classic Hodgkin lymphoma patients, but relapse is common. Allogeneic hematopoietic cell transplantation (alloHCT) after PD-1 blockade carries increased toxicity, with post-transplant cyclophosphamide (PTCy) prophylaxis showing significant improvements in progression-free survival (PFS) and graft-versus-host disease (GVHD)-free survival (GRFS).

LEUKEMIA (2021)

Add to Collection

Review Oncology

T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments

Naval Daver et al.

Summary: AML is a heterogeneous disease with a broad spectrum of molecular abnormalities, requiring multiple therapeutic approaches for long-term disease control. Recent advancements in understanding and targeting these molecular aberrations have led to rapid evolution in AML treatment, with a focus on immunotherapies harnessing T cells. Multiple T-cell-based immunotherapies, including bispecific antibodies, CAR T-cell therapies, and immune checkpoint inhibitors, are in various stages of development for AML treatment.

LEUKEMIA (2021)

Add to Collection

Article Oncology

A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia

Kapil Saxena et al.

Summary: Patients with relapsed/refractory acute myeloid leukemia (AML) have limited treatment options. The combination of azacitidine and the anti-PD-L1 immune checkpoint inhibitor avelumab showed limited clinical activity. High expression of PD-L2 on bone marrow blasts may contribute to resistance to anti-PD-L1 therapy in AML.

CANCER (2021)

Add to Collection

Article Oncology

Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia

Joshua F. Zeidner et al.

Summary: The study demonstrated that pembrolizumab following high-dose cytarabine in relapsed/refractory AML patients was well-tolerated and feasible, showing promising clinical activity, especially in refractory AML and those receiving treatment as first salvage regimen. Further exploration of pembrolizumab and other immune-checkpoint blockade strategies post cytotoxic chemotherapy is recommended in AML.

BLOOD CANCER DISCOVERY (2021)

Add to Collection

Article Oncology